Despite rising capital, Zhende Medical's dwindling ROCE hints a negative trend. Despite considerable past returns from the stock, the current trend may not promise a good long-term performance. The firm's reduction of liabilities to 21% of total assets, while good for operations, may further impede its ROCE.